• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Can We Afford to Exclude Patients Throughout Health Technology Assessment?在整个卫生技术评估过程中,我们能承担得起将患者排除在外的后果吗?
Front Med Technol. 2022 Jan 25;3:796344. doi: 10.3389/fmedt.2021.796344. eCollection 2021.
2
Strengthening international patient advocacy perspectives on patient involvement in HTA within the HTAi Patient and Citizen Involvement Interest Group - Commentary.在国际药物经济学与结果研究协会(HTAi)患者与公民参与兴趣小组中强化关于患者参与卫生技术评估(HTA)的国际患者倡导视角——评论
Res Involv Engagem. 2017 Jan 10;3:3. doi: 10.1186/s40900-016-0053-8. eCollection 2017.
3
Patient advocacy group involvement in health technology assessments: an observational study.患者权益倡导组织参与卫生技术评估:一项观察性研究。
Res Involv Engagem. 2021 Nov 25;7(1):83. doi: 10.1186/s40900-021-00327-5.
4
Patient advocate perspectives on involvement in HTA: an international snapshot.患者权益倡导者对参与卫生技术评估的看法:国际概览
Res Involv Engagem. 2017 Jan 10;3:2. doi: 10.1186/s40900-016-0052-9. eCollection 2017.
5
EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health Technology Assessment.欧洲患者参与药物研发指南:卫生技术评估
Front Med (Lausanne). 2018 Sep 6;5:231. doi: 10.3389/fmed.2018.00231. eCollection 2018.
6
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.避免和识别健康技术评估模型中的错误:定性研究和方法学综述。
Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250.
7
Patients and public are important stakeholders in health technology assessment but the level of involvement is low - a call to action.患者和公众是卫生技术评估中的重要利益相关者,但他们的参与程度较低——行动呼吁。
Res Involv Engagem. 2021 Jan 5;7(1):1. doi: 10.1186/s40900-020-00248-9.
8
Stories of Patient Involvement Impact in Health Technology Assessments: A Discussion Paper.患者参与影响卫生技术评估的故事:讨论文件。
Int J Technol Assess Health Care. 2019;35(4):266-272. doi: 10.1017/S0266462319000552. Epub 2019 Jul 24.
9
Health technology assessment in Australia: a role for clinical registries?澳大利亚的卫生技术评估:临床注册登记处能发挥作用吗?
Aust Health Rev. 2017 Mar;41(1):19-25. doi: 10.1071/AH15109.
10
Is it the Right Topic? An Overlooked Stage in the Institutionalization of Health Technology Assessment.是否为恰当主题?健康技术评估制度化过程中被忽视的阶段
Health Syst Reform. 2023 Dec 31;9(3):2329082. doi: 10.1080/23288604.2024.2329082. Epub 2024 May 7.

引用本文的文献

1
How to mobilise users' experiential knowledge in the evaluation of advanced technologies and practices in Quebec? The example of the permanent users' and relatives' panel.如何在魁北克的先进技术和实践评估中调动用户的经验知识?常设用户和亲属小组的例子。
Health Expect. 2024 Feb;27(1):e13964. doi: 10.1111/hex.13964.
2
Systematic review for the development of a core outcome set for monofocal intraocular lenses for cataract surgery.关于制定白内障手术单焦点人工晶状体核心结局集的系统评价。
Front Med (Lausanne). 2024 Feb 20;11:1339793. doi: 10.3389/fmed.2024.1339793. eCollection 2024.
3
Civil society and medical product access in Africa: Lessons from COVID-19.非洲的民间社会与医疗产品获取:来自新冠疫情的经验教训
Front Med Technol. 2023 Feb 7;5:1091425. doi: 10.3389/fmedt.2023.1091425. eCollection 2023.
4
Where National Medicines Policies Have Taken Us With Patient Involvement and Health Technology Assessment in Africa.非洲国家药品政策在患者参与和卫生技术评估方面的进展
Front Med Technol. 2022 Feb 24;4:810456. doi: 10.3389/fmedt.2022.810456. eCollection 2022.

本文引用的文献

1
The importance and value of engaging patients in cancer research.让患者参与癌症研究的重要性和价值。
Future Oncol. 2021 Oct;17(28):3663-3666. doi: 10.2217/fon-2021-0856. Epub 2021 Sep 10.
2
The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.意大利药品审评局(AIFA)注册系统的演变,以支持孤儿药品的有条件批准协议。
Front Pharmacol. 2021 Aug 10;12:699466. doi: 10.3389/fphar.2021.699466. eCollection 2021.
3
Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study.多发性骨髓瘤治疗的患者偏好:一项跨国定性研究。
Front Med (Lausanne). 2021 Jul 6;8:686165. doi: 10.3389/fmed.2021.686165. eCollection 2021.
4
Moral uncertainty: A case study of Covid-19.道德困境:新冠病毒案例研究。
Patient Educ Couns. 2021 Nov;104(11):2643-2647. doi: 10.1016/j.pec.2021.07.022. Epub 2021 Jul 15.
5
Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience.炎症性肠病综合护理单元:全国质量认证计划的评估。GETECCU 的经验。
United European Gastroenterol J. 2021 Sep;9(7):766-772. doi: 10.1002/ueg2.12105. Epub 2021 Jun 5.
6
Development of an international template to support patient submissions in Health Technology Assessments.开发一个国际模板,以支持患者提交健康技术评估材料。
Int J Technol Assess Health Care. 2021 Apr 1;37(1):e50. doi: 10.1017/S0266462321000167.
7
Mind the evidence gap: the use of patient-based evidence to create "complete HTA" in the twenty-first century.注意证据差距:在 21 世纪,利用基于患者的证据来创建“完整的 HTA”。
Int J Technol Assess Health Care. 2021 Mar 22;37:e46. doi: 10.1017/S026646232100012X.
8
(Re)defining legitimacy in Canadian drug assessment policy? Comparing ideas over time.(重新)定义加拿大药物评估政策的合法性?随时间比较观念的变化。
Health Econ Policy Law. 2021 Oct;16(4):424-439. doi: 10.1017/S1744133121000013. Epub 2021 Feb 9.
9
An institutional ethnographic analysis of public and patient engagement activities at a national health technology assessment agency.国家卫生技术评估机构中公众和患者参与活动的制度民族志分析。
Int J Technol Assess Health Care. 2021 Feb 9;37:e37. doi: 10.1017/S0266462321000088.
10
Patient and public involvement in health technology assessment: update of a systematic review of international experiences.患者和公众参与卫生技术评估:国际经验系统评价更新。
Int J Technol Assess Health Care. 2021 Feb 5;37:e36. doi: 10.1017/S0266462321000064.

在整个卫生技术评估过程中,我们能承担得起将患者排除在外的后果吗?

Can We Afford to Exclude Patients Throughout Health Technology Assessment?

作者信息

Wale Janet L, Chandler David, Collyar Deborah, Hamerlijnck Dominique, Saldana Roberto, Pemberton-Whitely Zack

机构信息

HTAi Patient and Citizen Involvement Interest Group (PCIG) Chair, Brunswick, VIC, Australia.

Psoriasis and Psoriatic Arthritis Alliance (PAPAA), St Albans, United Kingdom.

出版信息

Front Med Technol. 2022 Jan 25;3:796344. doi: 10.3389/fmedt.2021.796344. eCollection 2021.

DOI:10.3389/fmedt.2021.796344
PMID:35146487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8821945/
Abstract

Health technology assessment (HTA) is intended to determine the value of health technologies and, once a technology is recommended for funding, bridge clinical research and practice. Understanding the values and beliefs expressed by patients and health professionals can help guide this knowledge transfer and work toward managing the expectations of end users. We gathered patient and patient group leader experiences to gain insights into the roles that patients and patient advocacy groups are playing. We argue that through partnerships and co-creation between HTA professionals, researchers and patient advocates we can strengthen the HTA process and better align with service delivery where person-centered care and shared decision making are key elements. Patient experiences and knowledge are important to the democratization of evidence and the legitimacy of HTAs. Patient preference studies are used to balance benefits with potential harms of technologies, and patient-reported outcomes (PROs) can measure what matters to patients over time. A change in culture in HTA bodies is occurring and with further transformative thinking patients can be involved in every step of the HTA process. Patients have a right to be involved in HTAs, with patients' values central to HTA deliberations on a technology and where patients can provide valuable insights to inform HTA decision-making; and in ensuring that HTA methodologies evolve. By evaluating the implementation of HTA recommendations we can determine how HTA benefits patients and their communities. Our shared commitment can positively effect the common good and provide benefits to individual patients and their communities.

摘要

卫生技术评估(HTA)旨在确定卫生技术的价值,并且一旦某项技术被推荐获得资助,就要在临床研究和实践之间架起桥梁。了解患者和卫生专业人员所表达的价值观和信念有助于指导这种知识转移,并努力管理最终用户的期望。我们收集了患者及患者群体领导者的经验,以深入了解患者和患者倡导团体所发挥的作用。我们认为,通过卫生技术评估专业人员、研究人员和患者倡导者之间的伙伴关系与共同创造,我们可以加强卫生技术评估过程,并更好地与以患者为中心的护理和共同决策为关键要素的服务提供保持一致。患者的经验和知识对于证据的民主化以及卫生技术评估的合法性很重要。患者偏好研究用于平衡技术的益处与潜在危害,患者报告结局(PROs)可以衡量随着时间推移对患者重要的事情。卫生技术评估机构的文化正在发生变化,通过进一步的变革性思维,患者可以参与到卫生技术评估过程的每一个环节。患者有权参与卫生技术评估,患者的价值观是卫生技术评估对某项技术进行审议的核心,患者可以提供有价值的见解以指导卫生技术评估决策;并且在确保卫生技术评估方法不断发展方面。通过评估卫生技术评估建议的实施情况,我们可以确定卫生技术评估如何使患者及其社区受益。我们的共同承诺可以对共同利益产生积极影响,并为个体患者及其社区带来益处。